Novara Biotech reports quarterly revenue above the internal plan
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
Novara Biotech
Healthcare · Biotechnology
Updated UTC
410,77 US$
+5,46+1,35 %
After hours412,82 US$+0,50 %
| Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 31,67 mil M | 37,26 mil M | 41,96 mil M | 48,31 mil M | 53,67 mil M |
| Gross profit | 18,76 mil M | 21,53 mil M | 23,9 mil M | 26,46 mil M | 32,34 mil M |
| Operating income | 6256,39 M | 7619,98 M | 7845,39 M | 9580,62 M | 11,72 mil M |
| Net income | 4883,1 M | 5629,58 M | 6171,13 M | 5775,42 M | 7645,85 M |
Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
The company approved a multi-year capital program intended to shorten lead times for its largest customers.
Sector Desk
A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.
Sector Desk
The board named an internal candidate with prior treasury and investor-relations experience to the role.
Sector Desk
The authorization covers a modest slice of the float and will be funded from operating cash flow.
Terminal Brief